目的：观察并对比紫杉醇和奈达铂诱导化疗联合同期放化疗与单纯同期放化疗治疗晚期鼻咽癌的临床研究效果。方法：选取本院2013年2月-2014年3月收治的晚期鼻咽癌患者100例，将其作为临床研究对象，采用随机数字表法将其分为两组，对照组采用单纯同期放化疗进行治疗，试验组采用紫杉醇和奈达铂诱导化疗联合同期放化疗进行治疗，对患者的肿瘤控制情况进行比较。结果：试验组采用诱导化疗联合同期放化疗治疗的总有效率为96.00%，对照组采用单纯同期放化疗治疗的总有效率为70.00%，两组比较差异有统计学意义（P<0.05）；在安全性比较方面，对照组出现2例不良反应，观察组出现1例不良反应，两组比较差异无统计学意义（P>0.05）；试验组1年和2年后局部区域控制率、无远处转移生存率均高于对照组，两组1年和2年生存率差异无统计学意义。结论：采用诱导化疗联合同期放化疗治疗晚期鼻咽癌的临床效果较为明显，整体过程安全可靠，患者以及患者家属较为满意，因此值得在临床上广泛应用。%Objective:To observe and compare the effect of induction chemotherapy with Paclitaxel and Nedaplatin combined with concurrent chemoradiotherapy and alone aoncurrent chemoradiotherapy in treatment of advanced nasopharyngeal carcinoma.Method:100 cases of advanced nasopharyngeal carcinoma patients were selected from our hospital from February 2013 to March 2014,and they were randomly divided into two groups,one was control group and the other was experiment group,the control group was treated by alone concurrent chemoradiotherapy,the experiment group were treated by induction chemotherapy with Paclitaxel and Nedaplatin combined with concurrent chemoradiotherapy,and then we compared the two groups of patients’s tumor control results.Result:In total efficacy rate,the experiment group was 96.00%,and the control group was 70.00%,the difference was significant(P<0.05). In treatment security,there were 2 cases with adverse reactions in control group,and there were 1 cases with adverse reactions in experiment group,the difference was not significant(P>0.05).Observation group 1 and 2 years after local regional control rate,distant metastasis-free survival rates were higher in both groups 1 and 2-year survival difference was not statistically significant.Conclusion:Induction chemotherapy combined with concurrent chemoradiotherapy has a good effect in treatment of advanced nasopharyngeal carcinoma,the whole treatment process is safe and reliable,and also patients and family members satisfy for the treatment,so it is worth to promote in clinical.
展开▼
